RxDoctor Payments Data

Mikhail Radivilov, MD

Internal Medicine · Lakeland, FLNPI 1720050966

Payments from drug & device makers

$2,719in general payments, 2019–2025

Across 143 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$638
  • Pfizer$477
  • Novartis$443
  • Novo Nordisk$358
  • Abbott$234
  • Amgen$119
  • plus $450 from 11 others

What the payments were for

  • Food & beverage$2,68799%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,719 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$192,991
Medicare patients
561
Services billed
2,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$154,356
OzempicSemaglutide123$123,954
RybelsusSemaglutide66$97,215
MounjaroTirzepatide66$71,393
JardianceEmpagliflozin68$57,599
FarxigaDapagliflozin Propanediol47$56,586
GlyxambiEmpagliflozin/Linagliptin36$42,465
XareltoRivaroxaban26$33,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$32,920
TradjentaLinagliptin25$31,038
ArexvyRsvpref3 Antigen/As01e/Pf91$27,659
MyrbetriqMirabegron18$22,486
Soliqua 100-33Insulin Glargine/Lixisenatide16$20,645
LinzessLinaclotide11$16,352
Trijardy XrEmpaglifloz/Linaglip/Metformin13$11,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$358$221,169189 claims
PfizerEliquis$477$154,356159 claims
Lilly USA, LLCMounjaro, Trulicity$23$82,87077 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$70$71,109176 claims
AbbVieLinzess, Synthroid$638$20,89480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →